Early Detection of Acute Renal Injury in Blood and Marrow Transplant Patients Using Urinary Proteomics

What is the purpose of this study?

The purpose of this research study is to find out if urine obtained from patients who are undergoing a blood or marrow transplant, contains proteins that can help predict if the kidneys have been injured. Kidneys can be injured from the chemotherapy, from infections, and/or from other medications used during transplantation. Early detection of kidney damage and kidney failure after blood and marrow transplantation would help us to find new ways to prevent further damage as well as find new ways to treating kidney damage and kidney failure.

Who will be included?

Children who have been diagnosed with a condition requiring a blood/marrow transplant.

What samples/information do we need?

Only urine will be collected for this study, no blood will be obtained specifically for this research study. Your medical information will also be collected.

What is involved?

A urine sample will be collected on the day of admission to the hospital for your transplant and then daily from day -3 through day +21 of transplant.

What will be done with the samples?

Your urine will be tested in the research laboratory for early markers of kidney damage. Results of the urine tests will be studied along with information in your medical record. No other procedures are included in this study.

Collection and Storage of Personal and Medical Information:

Researchers in this study will gather information about your medical history from your chart. The researchers will also review the chart to obtain information about the bone marrow transplant such as laboratory data, exams and physician progress notes.

The information from the research study may be published; however, you will not be identified in such publication.

What are the benefits?

If you agree to take part in this research study, there will not be a direct medical benefit for you. The information learned from this research study may benefit other patients with an immune disorder in the future.

Will I get all the facts about the study?

If you are interested in participating in this study, you will meet with a study coordinator who will explain all of the details of the study. The study coordinator will review the consent form and will be sure that all questions are answered. The consent form describes all the procedures, risks, benefits and who to contact with questions or concerns. Study

procedures will not begin until the consent has been signed by the patient (if over 18 years) or the parent/guardian of the patient.

What are the risks?

A detailed list of possible risks will be provided to those patients interested in knowing more about the study.

Who should I contact for more information?

Angela Poston
Cincinnati Children's Hospital Medical Center
Division of Hematology/Oncology
3333 Burnet Ave.
Cincinnati, Ohio 45229-3039
Phone: 513-636-8815
angela.poston@cchmc.org